Sunday, March 25, 2018 9:32:10 AM
Private Placement of Common Stock and Warrants and Shares Issued Upon Conversion of Promissory Note
On January 19, 2018 and February 16, 2018, we issued and sold an aggregate of 32,500,000 shares of our common stock and warrants to purchase 44,200,000 shares of our common stock for aggregate gross proceeds of $3,250,000. We will not receive any proceeds from the sale of shares sold by the selling stockholders. However, we will receive proceeds of $0.10 per share upon the exercise of the warrants for cash. On December 28, 2017, we entered into a secured convertible promissory note pursuant to which Emerald Health Sciences Inc. (“Emerald”) agreed to loan to us up to $900,000. We received $500,000 on December 28, 2017 and the remaining $400,000 on January 19, 2018, at which time the secured convertible promissory note was converted into 9,000,000 shares of common stock at a conversion price of $0.10 per share of common stock
As part of the terms of the Agreement, we entered into a registration rights agreement pursuant to which we agreed to file a registration statement to register for resale the shares of common stock and the shares of common stock underlying the warrants sold in the private placement and issued upon conversion of the secured convertible promissory note. We agreed to use our best efforts to keep the registration statement effective under the Securities Act until the earlier of (i) the date as of which the purchasers may sell all of their shares without restriction or limitation pursuant to Rule 144 and without the requirement to be in compliance with Rule 144(c)(1) or (ii) the date on which the selling stockholders have sold all of the shares covered by the registration statement. We are filing this Registration Statement in order to fulfill our obligation under this registration rights agreement.
"Our houses are such unwieldy property that we are often imprisoned rather than housed in them." - Henry David Thoreau, Walden: Economy, 1854
Recent SKYE News
- Beacon Biosignals Announces Strategic Collaboration with Skye Bioscience to Integrate Sleep Quality and Sleep Apnea Endpoints in CBEYOND™ Phase 2 Trial of Nimacimab for Obesity • GlobeNewswire Inc. • 07/24/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 01:27:39 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/20/2024 04:15:09 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/17/2024 08:27:44 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/10/2024 08:19:14 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/10/2024 08:17:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:02:13 PM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM